Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
3.040
+0.110 (3.75%)
At close: Apr 28, 2026, 4:00 PM EDT
2.980
-0.060 (-1.97%)
After-hours: Apr 28, 2026, 7:27 PM EDT
Cyclerion Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 2.07 | 2 | - | 0.3 | 3.94 | |
| Revenue Growth (YoY) | 3.70% | - | - | -92.47% | 71.69% | |
| Cost of Revenue | 0.96 | 0.29 | 1.32 | 5.58 | 37.64 | |
| Gross Profit | 1.12 | 1.71 | -1.32 | -5.28 | -33.69 | |
| Selling, General & Admin | 6.09 | 5.34 | 8.33 | 13.26 | 20.62 | |
| Operating Expenses | 6.09 | 5.34 | 8.33 | 13.26 | 20.62 | |
| Operating Income | -4.97 | -3.63 | -9.65 | -18.54 | -54.31 | |
| Interest Expense | - | - | - | - | -0.02 | |
| Interest & Investment Income | 0.13 | 0.21 | 0.36 | 0.29 | - | |
| Other Non Operating Income (Expenses) | - | 0.36 | - | - | - | |
| EBT Excluding Unusual Items | -4.85 | -3.06 | -9.29 | -18.25 | -54.33 | |
| Asset Writedown | - | - | -3.3 | - | - | |
| Other Unusual Items | - | - | - | - | 2.68 | |
| Pretax Income | -3.53 | -3.06 | -12.59 | -18.25 | -51.65 | |
| Earnings From Continuing Operations | -3.53 | -3.06 | -12.59 | -18.25 | -51.65 | |
| Earnings From Discontinued Operations | - | - | 7.33 | -25.83 | - | |
| Net Income | -3.53 | -3.06 | -5.26 | -44.08 | -51.65 | |
| Net Income to Common | -3.53 | -3.06 | -5.26 | -44.08 | -51.65 | |
| Shares Outstanding (Basic) | 3 | 3 | 2 | 2 | 2 | |
| Shares Outstanding (Diluted) | 3 | 3 | 2 | 2 | 2 | |
| Shares Change (YoY) | 26.33% | 7.70% | 7.59% | 11.03% | 28.75% | |
| EPS (Basic) | -1.11 | -1.21 | -2.25 | -20.28 | -26.39 | |
| EPS (Diluted) | -1.11 | -1.21 | -2.25 | -20.28 | -26.39 | |
| Free Cash Flow | -3.31 | -4.33 | -21.25 | -40.61 | -36.52 | |
| Free Cash Flow Per Share | -1.04 | -1.72 | -9.09 | -18.69 | -18.66 | |
| Gross Margin | 53.76% | 85.70% | - | - | - | |
| Operating Margin | -239.78% | -181.40% | - | -6242.42% | -1377.83% | |
| Profit Margin | -170.11% | -152.85% | - | -14841.08% | -1310.17% | |
| Free Cash Flow Margin | -159.79% | -216.65% | - | -13673.74% | -926.53% | |
| EBITDA | - | - | -9.58 | -18.48 | -53.84 | |
| D&A For EBITDA | - | - | 0.07 | 0.07 | 0.47 | |
| EBIT | -4.97 | -3.63 | -9.65 | -18.54 | -54.31 | |
| EBIT Margin | -239.78% | -181.40% | - | - | - | |
| Revenue as Reported | 2.07 | 2 | - | 0.3 | 3.94 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.